Etanercept seems beneficial in partial spinal cord injury

Etanercept seems beneficial in partial spinal cord injury
Treatment of rabbits with a partial spinal cord injury with the intramuscularly-administered tumor necrosis factor-α inhibitor etanercept is associated with improved clinical and electrophysiological recovery processes, according to research published in the December issue of the European Spine Journal.

(HealthDay)—Treatment of rabbits with a partial spinal cord injury (SCI) with the intramuscularly-administered tumor necrosis factor-α (TNF-α) inhibitor etanercept is associated with improved clinical and electrophysiological recovery processes, according to research published in the December issue of the European Spine Journal.

Fatih Bayrakli, M.D., of the Cumhuriyet University School of Medicine in Sivas, Turkey, and colleagues conducted an animal study involving 24 rabbits with partial SCI who were treated with either intramuscular saline or 2.5 mg/kg administered two to four hours after SCI or 12 to 24 hours after SCI.

The researchers found that Tarlov scores were significantly better in the two groups administered intramuscular etanercept, compared with the group that received saline. Two weeks after SCI, somatosensory-evoked potential recovery was significantly improved in both groups that received etanercept.

"Our results show that blocking the inflammation process in SCI by anti-TNF-α agent enhances clinical and electrophysiological recovery," the authors write. "These results are preliminary and will be a foundation for further studies using our SCI model and provide evidence of decreased inflammation, which is not sufficiently found in literature. These results also must be confirmed with different models, different drug doses, compression pressures, and drug timing schedules with further investigations."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Ebola vaccine promising in first human trials

6 hours ago

Researchers say they are one step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.

At one month, US Ebola monitors finding no cases

9 hours ago

The U.S. program that requires weeks of monitoring for travelers from African countries with Ebola reaches the one-month mark Thursday. And so far, no cases of the disease have turned up.

EU calls for 5,000 doctors to fight Ebola

9 hours ago

The European Commission called for 5,000 doctors to be sent from EU states to combat west Africa's Ebola epidemic, a European source with knowledge of the matter said on Wednesday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.